PCLOF Stock Chart & Stats
$0.01
<$0.01(6.14%)
At close: 4:00 PM EST
$0.01
<$0.01(6.14%)
Day’s Range― - ―
52-Week Range<$0.01 - $0.12
Previous CloseN/A
Volume1.75K
Average Volume (3M)9.90K
Market Cap
$9.39M
Enterprise Value$34.34M
Total Cash (Recent Filing)$289.24K
Total Debt (Recent Filing)$18.65M
Price to Earnings (P/E)―
Beta-1.64
Next Earnings
Aug 14, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding211,283,630
10 Day Avg. Volume17,743
30 Day Avg. Volume9,897
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)-0.55
Price to Sales (P/S)3.24
P/FCF Ratio-8.30
Enterprise Value/Market Cap3.66
Enterprise Value/Revenue13.15
Enterprise Value/Gross Profit45.39
Enterprise Value/Ebitda-34.25
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Gross MarginA positive gross margin (~29%) indicates the core cultivation and extraction economics can be profitable at the product level. Persisting product-level margins give the company a structural opportunity to move toward operating leverage as volumes or utilization rise, supporting long-term margin recovery if SG&A and overhead are controlled.
Improving Cash BurnMaterial reduction in cash burn versus earlier years signals durable progress on cost control and operational efficiency. Structural improvements (lower run-rate cash outflows) reduce near-term refinancing needs and create a clearer path to break-even if sustained through steady revenue and continued margin discipline.
B2B Standardized Product ModelA B2B focus on standardized cannabinoid inputs targets formulators and institutional customers, which tends to yield stickier contracts and repeatable volumes. This business model leverages process standardization and regulatory know-how, creating a defensible niche versus fragmented retail channels over the medium term.
Bears Say
Declining RevenueA continuing revenue decline and volatile top line undermine sustainable scale: production capacity and fixed costs become harder to cover, and recovery of operating margins is impeded. Without consistent revenue growth, the company’s ability to convert positive gross margins into operating profitability remains uncertain.
Negative Equity And High LeverageSubstantial negative equity and debt levels materially above the asset base indicate weakened solvency and constrained financial flexibility. This structural leverage raises refinancing and creditor risk, limiting the company’s ability to invest in growth or withstand industry headwinds without dilutive or costly external funding.
Persistent Negative Cash FlowOngoing negative OCF and FCF mean the business continues to consume cash and depend on external financing. Structurally, this reduces capacity to reinvest in production or R&D, heightens liquidity risk, and leaves the company exposed to funding cycles absent sustained margin and revenue improvement.
PharmaCielo News
PCLOF FAQ
What was PharmaCielo’s price range in the past 12 months?
PharmaCielo lowest stock price was <$0.01 and its highest was $0.12 in the past 12 months.
What is PharmaCielo’s market cap?
PharmaCielo’s market cap is $9.39M.
When is PharmaCielo’s upcoming earnings report date?
PharmaCielo’s upcoming earnings report date is Aug 14, 2026 which is in 34 days.
How were PharmaCielo’s earnings last quarter?
Currently, no data Available
Is PharmaCielo overvalued?
According to Wall Street analysts PharmaCielo’s price is currently Overvalued.
Does PharmaCielo pay dividends?
PharmaCielo does not currently pay dividends.
What is PharmaCielo’s EPS estimate?
PharmaCielo’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does PharmaCielo have?
PharmaCielo has 211,283,630 shares outstanding.
What happened to PharmaCielo’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of PharmaCielo?
Currently, no hedge funds are holding shares in PCLOF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
PharmaCielo
PharmaCielo Ltd., operating in conjunction with its subsidiary, is primarily engaged in the comprehensive cultivation, processing, and distribution of pharmaceutical-grade cannabis extracts, including tetrahydrocannabinol (THC), and associated medicinal products. Additionally, the company diversifies its offerings by providing telemedicine software. Its clientele spans a range of entities, such as health and wellness product manufacturers, pharmacies, medical clinics, and cosmetic companies, across both Canada and Colombia. PharmaCielo also holds a strategic partnership with AssuredTrans Inc., and its corporate headquarters are situated in Toronto, Canada.
Technical Analysis
Willow Biosciences Inc
―
MediPharm Labs
―
Nextleaf Solutions
―
Avicanna
―
InnoCan Pharma
―
Ownership Overview
14.65% Insiders
0.15% Other Institutional Investors
85.06% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---